Longboard Pharmaceuticals’ bexicaserin was granted FDA orphan designation as a treatment of Dravet syndrome, according to a post to the agency’s website.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals initiated with a Buy at Truist
- Longboard announces interim analysis results from OLE Phase 1b/2a PACIFIC study
- Truist healthcare analyst holds an analyst/industry conference call
- Longboard Pharmaceuticals price target raised to $45 from $36 at B. Riley
- Longboard Pharmaceuticals price target raised to $50 from $45 at Citi